RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
NewGLab Pharma Co Stock

NewGLab Pharma Co Debt 2024

NewGLab Pharma Co Debt

37,023.05 KRW

Ticker

214870.KQ

ISIN

KR7214870008

In 2024, NewGLab Pharma Co's total debt was 37,023.05 KRW, a 17.88% change from the 31,406.93 KRW total debt recorded in the previous year.

NewGLab Pharma Co Aktienanalyse

What does NewGLab Pharma Co do?

NewGLab Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding NewGLab Pharma Co's Debt Structure

NewGLab Pharma Co's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing NewGLab Pharma Co's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to NewGLab Pharma Co’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in NewGLab Pharma Co’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about NewGLab Pharma Co stock

What is the debt of NewGLab Pharma Co this year?

NewGLab Pharma Co has a debt level of 37,023.05 KRW this year.

What was the debt of NewGLab Pharma Co compared to the previous year?

The debt of NewGLab Pharma Co has increased by 17.88% compared to the previous year increased.

What are the consequences of high debt for investors in NewGLab Pharma Co?

High debt can pose a risk for investors of NewGLab Pharma Co, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of NewGLab Pharma Co?

Low debt means that NewGLab Pharma Co has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from NewGLab Pharma Co affect the company?

An increase in debt of NewGLab Pharma Co can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of NewGLab Pharma Co affect the company?

A reduction in debt of NewGLab Pharma Co can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of NewGLab Pharma Co?

Some factors that can influence the debt of NewGLab Pharma Co include investments, acquisitions, operating costs, and revenue development.

Why are the debts of NewGLab Pharma Co so important for investors?

The debts of NewGLab Pharma Co are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can NewGLab Pharma Co take to change the debt?

To change the debt, NewGLab Pharma Co can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does NewGLab Pharma Co pay?

Over the past 12 months, NewGLab Pharma Co paid a dividend of 25 KRW . This corresponds to a dividend yield of about 0.36 %. For the coming 12 months, NewGLab Pharma Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of NewGLab Pharma Co?

The current dividend yield of NewGLab Pharma Co is 0.36 %.

When does NewGLab Pharma Co pay dividends?

NewGLab Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of NewGLab Pharma Co?

NewGLab Pharma Co paid dividends every year for the past 0 years.

What is the dividend of NewGLab Pharma Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is NewGLab Pharma Co located?

NewGLab Pharma Co is assigned to the 'Information technology' sector.

Wann musste ich die Aktien von NewGLab Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of NewGLab Pharma Co from 4/20/2016 amounting to 50 KRW, you needed to have the stock in your portfolio before the ex-date on 12/29/2015.

When did NewGLab Pharma Co pay the last dividend?

The last dividend was paid out on 4/20/2016.

What was the dividend of NewGLab Pharma Co in the year 2023?

In the year 2023, NewGLab Pharma Co distributed 0 KRW as dividends.

In which currency does NewGLab Pharma Co pay out the dividend?

The dividends of NewGLab Pharma Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von NewGLab Pharma Co

Our stock analysis for NewGLab Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NewGLab Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.